Can 68 Ga-prostate specific membrane antigen positron emission tomography/computerized tomography provide an accurate ly
- PDF / 923,357 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 88 Downloads / 176 Views
Open Access
RESEARCH
Can 68Ga‑prostate specific membrane antigen positron emission tomography/ computerized tomography provide an accurate lymph node staging for patients with medium/ high risk prostate cancer? A diagnostic meta‑analysis Lei Peng1†, Jinze Li1†, Chunyang Meng1†, Jinming Li2, Chengyu You1, Dandan Tang3, Tangqiang Wei1, Wei Xiong1 and Yunxiang Li1*
Abstract Objective: This article aims to evaluate the diagnostic value of 68Gallium-PSMA positron emission tomography/computerized tomography (68Ga-PSMA PET/CT) for lymph node (LN) staging in patients with prostate cancer (PCa) by a meta-analysis of diagnostic tests. Methods: We systematically retrieved articles from Web of Science, EMBASE, Cochrane Database, PubMed. The time limit is from the creation of the database until June 2019, and Stata 15 was used for calculation and statistical analyses. Results: Sensitivity, specificity, positive and negative likelihood ratio (PLR, NLR), diagnostic odds ratio (DOR) and 95% confidence intervals (CI) be used to evaluate the diagnostic value. A total of 10 studies were included in our metaanalysis, which included 701 individuals. The results of each consolidated summary are as follows: sensitivity of 0.84 (95% CI 0.55–0.95), specificity of 0.95 (95% CI 0.87–0.98), PLR and NLR was 17.19 (95% CI 6.27, 47.17) and 0.17 (95% CI 0.05–0.56), respectively. DOR of 100 (95% CI 18–545), AUC of 0.97 (95% CI 0.95–0.98). Conclusion: Our study demonstrates that 68Ga-PSMA PET/CT has a high overall diagnostic value for LN staging in patients with moderate and high-risk PCa. But our conclusions still require a larger sample size, multi-center prospective randomized controlled trial to verify. Keywords: Prostate cancer, Lymph node, 68Gallium- prostate-specific membrane antigen, Meta-analysis
*Correspondence: [email protected] † Lei Peng, Jinze Li, Chunyang Meng have contributed equally to this work. 1 Department of Urology, The Second Affiliated Hospital of Medical College, Nanchong Central Hospital, North Sichuan Medical College, Nanchong 63700, Sichuan, China Full list of author information is available at the end of the article
Introduction Prostate cancer (PCa) is the second most common cancer and the fifth leading cause of cancer death in developed countries [1]. Although the clinical symptoms of early PCa are not obvious, pelvic lymph node (LN) and bone metastasis are also prone to occur [2]. About 15% of patients with medium and high-risk prostate cancer were found to have harbor lymph node invasion when
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a cred
Data Loading...
